NCT05689619View on ClinicalTrials.gov

SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)

NARecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2027

Conditions
Brain Metastases, AdultNon Small Cell Lung CancerBreast Cancer
Interventions
DIETARY_SUPPLEMENT

Silibinin

Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC

OTHER

Placebo

Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC

Trial Locations (6)

10126

RECRUITING

Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin

Unknown

NOT_YET_RECRUITING

Unità Operativa di Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino di Genova, Genova

RECRUITING

Neurosurgery Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina

NOT_YET_RECRUITING

Institute of Neurosurgery, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Catholic University, Rome

NOT_YET_RECRUITING

Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome

NOT_YET_RECRUITING

Precision Medicine in Breast Cancer Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome

All Listed Sponsors
lead

A.O.U. Città della Salute e della Scienza

OTHER